• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pharming Group to report second quarter and first half 2024 financial results on August 1

    7/18/24 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAR alert in real time by email

    Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.



    Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024.

    To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

    Conference call registration:

    Please note, the Company will only take questions from dial-in attendees.

    https://register.vevent.com/register/BI92328f52b76d43d394cacc1c2ba94ac4

    To watch the live webcast, please register in advance using the link below.

    Webcast registration:

    https://edge.media-server.com/mmc/p/awvi6h6a/

    About Pharming Group N.V.

    Pharming Group N.V. (NASDAQ:PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

    For more information, visit www.pharming.com and find us on LinkedIn.

    For further public information, contact:

    Pharming Group, Leiden, the Netherlands

    Michael Levitan, VP Investor Relations & Corporate Communications

    T: +1 (908) 705 1696

    E: [email protected]

    FTI Consulting, London, UK

    Victoria Foster Mitchell/Alex Shaw/Amy Byrne

    T: +44 203 727 1000

    LifeSpring Life Sciences Communication, Amsterdam, The Netherlands

    Leon Melens

    T: +31 6 53 81 64 27

    E: [email protected]

    Attachment

    • Pharming Group to report 2Q24_1H24 results_EN_18JULY24


    Primary Logo

    Get the next $PHAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAR

    DatePrice TargetRatingAnalyst
    12/9/2024$14.00Buy
    Jefferies
    More analyst ratings

    $PHAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

      Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac

      3/4/25 9:15:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

      Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.

      1/21/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

      Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Dr. Richard Peters as Non-Executive director for a period of four years. As a result, Dr. Peters succeeds Mr. Paul Sekhri as Chair of the Board of Directors with immediate effect. Deborah Jorn, Vice-Chair of the Board of Directors, commented: "On behalf of the Board, I would like to thank our outgoing Chairman, Paul Sekhri, for his leadership, over the past eight years. During his tenure as Chairman, Paul a

      9/25/23 10:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care